BioBill @BioBill2

Gene therapy analyst Joined December 2020

Tweets

1K
Followers

1K
Following

93
Likes

808

Pengyu Yang @Pengyu19

4 years ago

Identification of #MRTX1133, a Noncovalent, Potent, and Selective #KRASG12D Inhibitor pubs.acs.org/doi/10.1021/ac…

1 18 75 0 5

$BPMC looking to start a position. Really excited for early look at BLU-701 and BLU-945. I like the combination idea to drive deep and and durable responses, potentially covering multiple acquired resistance mutations. Along with the ability to control CNS metastasis.

0 1 11 0 0

Robert Nelsen @rtnarch

4 years ago

The hospital system and doctors are partly to blame for the underuse of monoclonals, that can pretty much save most COVID death. I hear them complaining about full ICU’s but they won’t put an infusion tent in the parking lot. Tragedy. Govermment should have ordered them.

8 4 73 0 6

Breaking Biotech @MatthewLepoire

4 years ago

102 - Arvinas' PIONEERING PROTAC Tech to Enhance Cancer Outcomes | Interview with CEO John Houston $ARVN @ArvinasInc @JohnGHouston youtu.be/nmbD4HsraBE

3 2 11 0 2

Epoch @EpochSwing

4 years ago

Bicycle Therapeutics $BCYC has just fired a shot-heard-round-the-world, threatening to disrupt a huge technology platform in the biotech industry. Here's a play-by-play on David vs. Goliath, taking on antibody-drug conjugates! Thread below🧵

5 20 135 0 55

Keith Hornberger @KRHornberger

4 years ago

❗️BREAKING at @AACR #Targets21: Mirati Therapeutics has disclosed the structure of MRTX1133, their reversible KRAS G12D inhibitor. Fantastic story. Plus hints of a new pan-KRAS inhibitor. Congratulations!

6 106 427 0 38

Download Image

Epoch @EpochSwing

4 years ago

Today has been 🍿 War in BioTwitter and blood and gold in the streets. Had a wild ride on a $BCYC and watched a Sheep fight a Scorpion. Thanks all for the fun & commentary